Braun Stacey Associates Inc. Decreases Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Braun Stacey Associates Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 22,146 shares of the biopharmaceutical company’s stock after selling 1,172 shares during the period. Braun Stacey Associates Inc.’s holdings in Regeneron Pharmaceuticals were worth $23,281,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. boosted its holdings in Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 19 shares in the last quarter. Stephens Consulting LLC purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth about $26,000. Sachetta LLC boosted its holdings in Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Crewe Advisors LLC purchased a new stake in Regeneron Pharmaceuticals during the first quarter worth about $28,000. Finally, Lynx Investment Advisory purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth about $33,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Transactions at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the company’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This represents a 27.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $756.81 on Monday. Regeneron Pharmaceuticals, Inc. has a one year low of $753.69 and a one year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a 50 day moving average price of $985.21 and a 200 day moving average price of $1,034.89. The firm has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15.

Analyst Ratings Changes

REGN has been the topic of several recent research reports. Wells Fargo & Company reduced their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a report on Tuesday, October 22nd. Royal Bank of Canada reduced their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a report on Friday, November 1st. StockNews.com downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, November 4th. Guggenheim upped their price target on shares of Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the company a “buy” rating in a report on Friday, August 2nd. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 price target (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,099.55.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.